Neuropsychiatric symptoms, apolipoprotein E gene, and risk of progression to cognitive impairment, no dementia and dementia: the Aging, Demographics, and Memory Study (ADAMS)

Authors

  • Sherry A. Beaudreau,

    Corresponding author
    1. Stanford University School of Medicine, Stanford, CA, USA
    • Sierra Pacific Mental Illness Research, Education, and Clinical Center (MIRECC), Veterans Administration Palo Alto Health Care System, Palo Alto, CA, USA
    Search for more papers by this author
  • J. Kaci Fairchild,

    1. Stanford University School of Medicine, Stanford, CA, USA
    2. Sierra Pacific Mental Illness Research, Education, and Clinical Center (MIRECC), Veterans Administration Palo Alto Health Care System, Palo Alto, CA, USA
    Search for more papers by this author
  • Adam P. Spira,

    1. Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
    Search for more papers by this author
  • Laura C. Lazzeroni,

    1. Stanford University School of Medicine, Stanford, CA, USA
    Search for more papers by this author
  • Ruth O'Hara

    1. Stanford University School of Medicine, Stanford, CA, USA
    2. Sierra Pacific Mental Illness Research, Education, and Clinical Center (MIRECC), Veterans Administration Palo Alto Health Care System, Palo Alto, CA, USA
    Search for more papers by this author

Correspondence to: S. A. Beaudreau, E-mail: sherryb@stanford.edu

Abstract

Objective

To examine the relationship of neuropsychiatric symptoms and apolipoprotein E (APOE) ε4 allele status to dementia at baseline and progression to dementia in older adults with and without cognitive impairment, no dementia (CIND).

Methods

Adults (n = 856) 71 years and older (mean age = 79.15 years), 12.8% ethnic minority and 60.6% women, completed neuropsychological tests and APOE genotyping, and a proxy informant completed the Neuropsychiatric Inventory.

Results

After adjusting for age and education, neuropsychiatric symptoms and APOE ε4 were independently associated with CIND and dementia status at baseline (compared with cognitively normal). Further, neuropsychiatric symptoms predicted progression to dementia at 16- to 18-month follow-up among participants with CIND at baseline; the presence of these symptoms decreased the risk of progression from normal to CIND or dementia at 36 to 48 months.

Conclusion

Findings provide cross-sectional and longitudinal support for the role of neuropsychiatric symptoms in the prediction of cognitive impairment, particularly dementia. APOE ε4, although important, may be a less robust predictor. This investigation highlights the importance of behavioral symptoms, such as neuropsychiatric symptom status or frequency/severity, as predictors of future cognitive decline. Copyright © 2012 John Wiley & Sons, Ltd.

Ancillary